TherapeuticsMD, Inc. (TXMD) 10-Year Financial Performance & Capital Metrics

TXMD • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsWomen's Health Therapeutics

AboutTherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Show more

Revenue $2M +35.3%
EBITDA -$4M +47.4%
Net Income -$2M +78.8%
EPS (Diluted) -0.19 +74.3%
Gross Margin 100%
EBITDA Margin -241.4% +61.1%
Operating Margin -270.3% +58.7%
Net Margin -123.85% +84.3%
ROE -7.7% +75.9%
ROIC -11.43% +65.3%
Debt/Equity 0.26 -4.1%
Interest Coverage -501.05

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 93.0%
✓FCF machine: 41.6% free cash flow margin
✓Momentum leader: RS Rating 89 (top 11%)
✓Trading near 52-week high
✓Trading at only 0.9x book value

✗Weaknesses

✗Sales declining 48.7% over 5 years
✗Shares diluted 10.4% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-19.3%

5Y-48.72%

3Y-11.87%

TTM75.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM109.11%

EPS CAGR

10Y-

5Y-

3Y-

TTM108%

ROCE

10Y Avg-100.68%

5Y Avg-106.7%

3Y Avg-10.71%

Latest-13.58%

Peer Comparison

Women's Health Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TXMDTherapeuticsMD, Inc.	25.93M	2.24	-11.79	35.25%	10.8%	1.1%	2.82%	0.26

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	20.14M	19.36M	16.78M	16.1M	49.65M	64.87M	2.57M	69.96M	1.3M	1.76M
Revenue Growth %	0.34%	-0.04%	-0.13%	-0.04%	2.08%	0.31%	-0.96%	26.19%	-0.98%	0.35%
Cost of Goods Sold+	4.51M	4.19M	2.64M	2.74M	6.33M	15.97M	1.4M	1.4M	0	0
COGS % of Revenue	0.22%	0.22%	0.16%	0.17%	0.13%	0.25%	0.54%	0.02%	-	-
Gross Profit+	15.64M	15.17M	14.14M	13.36M	43.31M	48.9M	1.17M	68.57M	1.3M	1.76M
Gross Margin %	0.78%	0.78%	0.84%	0.83%	0.87%	0.75%	0.46%	0.98%	1%	1%
Gross Profit Growth %	0.38%	-0.03%	-0.07%	-0.06%	2.24%	0.13%	-0.98%	57.55%	-0.98%	0.35%
Operating Expenses+	100.83M	105.42M	91.77M	143.58M	194.52M	204.44M	80.75M	67.38M	9.82M	6.52M
OpEx % of Revenue	5.01%	5.45%	5.47%	8.92%	3.92%	3.15%	31.38%	0.96%	7.55%	3.7%
Selling, General & Admin	28.72M	51.35M	57.7M	115.99M	174.72M	194.01M	72.75M	56.71M	0	0
SG&A % of Revenue	1.43%	2.65%	3.44%	7.2%	3.52%	2.99%	28.27%	0.81%	-	-
Research & Development	72.04M	53.94M	33.85M	27.3M	19.79M	10.43M	0	0	0	0
R&D % of Revenue	3.58%	2.79%	2.02%	1.7%	0.4%	0.16%	-	-	-	-
Other Operating Expenses	95.72K	367.32K	695.63K	0	0	0	8M	10.66M	9.82M	6.52M
Operating Income+	-85.19M	-90.25M	-77.63M	-130.22M	-151.21M	-155.54M	-79.58M	1.19M	-8.52M	-4.76M
Operating Margin %	-4.23%	-4.66%	-4.63%	-8.09%	-3.05%	-2.4%	-30.93%	0.02%	-6.55%	-2.7%
Operating Income Growth %	-0.58%	-0.06%	0.14%	-0.68%	-0.16%	-0.03%	0.49%	1.01%	-8.16%	0.44%
EBITDA+	-85.13M	-90.12M	-77.42M	-129.93M	-149.81M	-151.47M	-78.84M	2.39M	-8.08M	-4.25M
EBITDA Margin %	-4.23%	-4.66%	-4.61%	-8.07%	-3.02%	-2.33%	-30.64%	0.03%	-6.21%	-2.41%
EBITDA Growth %	-0.58%	-0.06%	0.14%	-0.68%	-0.15%	-0.01%	0.48%	1.03%	-4.38%	0.47%
D&A (Non-Cash Add-back)	62.4K	132.45K	213.12K	293.89K	1.39M	4.07M	736K	1.2M	438.5K	509K
EBIT	-85.19M	-89.88M	-76.93M	-127.94M	-159.62M	-157.47M	-71.58M	10.66M	-8.52M	-3.49M
Net Interest Income+	17.44K	10.82K	7.7K	-4.68M	-17.38M	-28.58M	-32.92M	0	0	135.4K
Interest Income	17.44K	10.82K	7.7K	0	-	-	0	0	0	144.9K
Interest Expense	0	0	0	4.68M	17.38M	28.58M	32.92M	0	0	9.5K
Other Income/Expense	113.16K	378.14K	703.33K	-2.4M	-24.94M	-27.98M	272K	-117K	781K	2.42M
Pretax Income+	-85.08M	-89.88M	-76.93M	-132.62M	-176.15M	-183.52M	-79.31M	1.07M	-7.74M	-2.34M
Pretax Margin %	-4.22%	-4.64%	-4.58%	-8.24%	-3.55%	-2.83%	-30.82%	0.02%	-5.95%	-1.33%
Income Tax+	-17.44K	367.32K	-7.7K	0	0	0	0	0	-43K	-31K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	2.17%	104.28%	1.33%	0.93%
Net Income+	-85.08M	-89.88M	-76.93M	-132.62M	-176.15M	-183.52M	-172.41M	112M	-10.28M	-2.18M
Net Margin %	-4.22%	-4.64%	-4.58%	-8.24%	-3.55%	-2.83%	-67.01%	1.6%	-7.89%	-1.24%
Net Income Growth %	-0.57%	-0.06%	0.14%	-0.72%	-0.33%	-0.04%	0.06%	1.65%	-1.09%	0.79%
Net Income (Continuing)	-85.08M	-89.88M	-76.93M	-132.62M	-176.15M	-183.52M	-79.31M	1.07M	-7.7M	-2.31M
Discontinued Operations	0	0	0	0	0	0	-93.11M	110.92M	-2.58M	131K
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-24.56	-22.92	-18.71	-29.47	-39.79	-38.58	-25.83	-10.35	-0.74	-0.19
EPS Growth %	-0.36%	0.07%	0.18%	-0.58%	-0.35%	0.03%	0.33%	0.6%	0.93%	0.74%
EPS (Basic)	-24.56	-22.92	-18.71	-29.47	-39.79	-38.58	-25.83	-10.35	-0.55	-0.19
Diluted Shares Outstanding	3.46M	3.92M	4.11M	4.5M	4.93M	5.51M	7.96M	9.03M	10.44M	11.53M
Basic Shares Outstanding	3.46M	3.92M	4.11M	4.5M	4.93M	5.51M	7.96M	9.03M	10.44M	11.53M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	70.68M	139.41M	139.55M	186.78M	208.42M	128.4M	119.47M	55.35M	11.8M	9.93M
Cash & Short-Term Investments	64.71M	131.53M	127.14M	161.61M	160.83M	80.49M	64.91M	38.07M	4.33M	5.06M
Cash Only	64.71M	131.53M	127.14M	161.61M	160.83M	80.49M	64.91M	38.07M	4.33M	5.06M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	3.05M	4.5M	4.33M	11.06M	24.4M	32.38M	36.18M	0	3.09M	3.56M
Days Sales Outstanding	55.26	84.87	94.17	250.83	179.36	182.2	5.13K	-	866.24	738.29
Inventory	690.15K	1.08M	1.49M	3.27M	11.86M	7.99M	7.62M	0	0	0
Days Inventory Outstanding	55.9	93.86	205.6	435.67	683.37	182.63	1.98K	-	-	-
Other Current Assets	833.84K	0	0	1.9M	550.76K	4.98M	8.46M	16.12M	4.13M	1.23M
Total Non-Current Assets+	3.05M	3.06M	3.68M	25.2M	57.57M	53.21M	50M	35.11M	31.51M	28.9M
Property, Plant & Equipment	198.59K	516.84K	437.06K	472.68K	12.62M	11.51M	9.06M	7.66M	6.87M	6.1M
Fixed Asset Turnover	101.43x	37.45x	38.39x	34.06x	3.93x	5.64x	0.28x	9.14x	0.19x	0.29x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.62M	2.41M	3.1M	24.09M	44.48M	41.45M	7.14M	6.94M	6.1M	4.32M
Long-Term Investments	0	0	0	0	0	0	0	0	0	16.01M
Other Non-Current Assets	1.23M	139.04K	139.04K	639.3K	473.01K	253K	33.8M	20.51M	18.54M	2.46M
Total Assets+	73.73M	142.47M	143.23M	211.98M	265.99M	181.61M	169.47M	90.46M	43.31M	38.82M
Asset Turnover	0.27x	0.14x	0.12x	0.08x	0.19x	0.36x	0.02x	0.77x	0.03x	0.05x
Asset Growth %	0.25%	0.93%	0.01%	0.48%	0.25%	-0.32%	-0.07%	-0.47%	-0.52%	-0.1%
Total Current Liabilities+	10.67M	14.98M	13.32M	41.08M	53M	59.24M	252.89M	46.84M	6.85M	5.17M
Accounts Payable	3.13M	7.36M	4.1M	22.74M	19.18M	21.07M	3.37M	2.16M	27K	258K
Days Payables Outstanding	253.19	641.67	567.18	3.03K	1.11K	481.37	878.13	564.87	-	-
Short-Term Debt	0	0	0	0	0	0	188.27M	0	0	1.63M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	14.13M	7.06M	47.91M	30.53M	3.69M	3.16M
Current Ratio	6.63x	9.30x	10.48x	4.55x	3.93x	2.17x	0.47x	1.18x	1.72x	1.92x
Quick Ratio	6.56x	9.23x	10.36x	4.47x	3.71x	2.03x	0.44x	1.18x	1.72x	1.92x
Cash Conversion Cycle	-142.03	-462.95	-267.41	-2.35K	-242.42	-116.54	6.24K	-	-	-
Total Non-Current Liabilities+	0	0	0	73.38M	203.78M	246.37M	10.2M	8.48M	7.17M	6.29M
Long-Term Debt	0	0	0	73.38M	194.63M	237.7M	0	0	0	0
Capital Lease Obligations	0	0	0	0	9.15M	8.68M	8.06M	7.37M	6.53M	5.54M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	2.14M	1.11M	636K	744K
Total Liabilities	10.67M	14.98M	13.32M	114.46M	256.78M	305.61M	263.09M	55.31M	14.02M	11.45M
Total Debt+	0	0	0	73.38M	205.28M	248.63M	197.69M	8.76M	8.01M	7.17M
Net Debt	-64.71M	-131.53M	-127.14M	-88.23M	44.45M	168.14M	132.79M	-29.31M	3.68M	2.12M
Debt / Equity	-	-	-	0.75x	22.31x	-	-	0.25x	0.27x	0.26x
Debt / EBITDA	-	-	-	-	-	-	-	3.66x	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-12.26x	-	-
Interest Coverage	-	-	-	-27.84x	-8.70x	-5.44x	-2.42x	-	-	-501.05x
Total Equity+	63.06M	127.49M	129.91M	97.52M	9.2M	-124M	-93.62M	35.14M	29.29M	27.37M
Equity Growth %	0.3%	1.02%	0.02%	-0.25%	-0.91%	-14.48%	0.24%	1.38%	-0.17%	-0.07%
Book Value per Share	18.21	32.51	31.60	21.67	1.87	-22.49	-11.76	3.89	2.81	2.37
Total Shareholders' Equity	63.06M	127.49M	129.91M	97.52M	9.2M	-124M	-93.62M	35.14M	29.29M	27.37M
Common Stock	177.93K	196.69K	216.43K	240.46K	271.18K	300K	9K	9K	11K	11K
Retained Earnings	-219.83M	-309.7M	-386.66M	-519.28M	-695.42M	-878.95M	-1.05B	-939.36M	-949.64M	-951.82M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-152.71K	-230.62K	-372.22K	-553.63K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-79.04M	-69.14M	-76.16M	-106.81M	-165.7M	-159.47M	-147.81M	-4.08M	-48.14M	732K
Operating CF Margin %	-3.92%	-3.57%	-4.54%	-6.63%	-3.34%	-2.46%	-57.45%	-0.06%	-36.97%	0.42%
Operating CF Growth %	-0.74%	0.13%	-0.1%	-0.4%	-0.55%	0.04%	0.07%	0.97%	-10.81%	1.02%
Net Income	-85.08M	-89.88M	-76.93M	-132.62M	-176.15M	-183.52M	-79.31M	1.07M	-7.7M	-2.31M
Depreciation & Amortization	62.4K	132.45K	213.12K	293.89K	1.39M	4.07M	736K	1.19M	922K	509K
Stock-Based Compensation	7.19M	17.41M	6.89M	8.66M	10.68M	10.68M	0	11.57M	0	0
Deferred Taxes	0	0	0	216.02K	10.44M	0	0	0	0	0
Other Non-Cash Items	22.16K	2.52M	4.21K	269.86K	1.92M	12.65M	-73.83M	-13.83M	-23.92M	875K
Working Capital Changes	-1.24M	664.75K	-6.34M	16.36M	-14M	-3.34M	4.59M	-4.09M	-17.45M	1.66M
Change in Receivables	-917.66K	-3.98M	167.69K	-6.95M	-13.64M	-8.22M	-4.33M	0	0	0
Change in Inventory	491.96K	-386.17K	-409.04K	-1.78M	-8.59M	-3.34M	-711K	0	0	0
Change in Payables	-3.2M	4.23M	-3.26M	18.65M	-3.56M	1.89M	-1.06M	-1.21M	-2.13M	231K
Cash from Investing+	-584.36K	-1.26M	-827.11K	-21.5M	-23.91M	-1.6M	-2.22M	223.48M	0	0
Capital Expenditures	-584.36K	-1.24M	-827.11K	-21.32M	-23.89M	-207K	-2.22M	-355K	0	0
CapEx % of Revenue	0.03%	0.06%	0.05%	1.32%	0.48%	0%	0.86%	0.01%	36.97%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-419.1K	-14.04K	-765.29K	-175.41K	-20.42K	-1.39M	0	223.83M	0	0
Cash from Financing+	92.97M	137.23M	72.58M	162.79M	188.83M	80.72M	134.67M	-235.21M	3.15M	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.6M	2.36M	4.01M	-2.12M	-6.54M	-978K	0	-1.27M	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-79.63M	-70.38M	-76.98M	-128.13M	-189.59M	-161.07M	-147.84M	-4.43M	0	732K
FCF Margin %	-3.95%	-3.64%	-4.59%	-7.96%	-3.82%	-2.48%	-57.46%	-0.06%	-	0.42%
FCF Growth %	-0.73%	0.12%	-0.09%	-0.66%	-0.48%	0.15%	0.08%	0.97%	1%	-
FCF per Share	-22.99	-17.95	-18.73	-28.47	-38.48	-29.22	-18.57	-0.49	-	0.06
FCF Conversion (FCF/Net Income)	0.93x	0.77x	0.99x	0.81x	0.94x	0.87x	0.86x	-0.04x	4.68x	-0.34x
Interest Paid	0	0	0	0	0	25.85M	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-152.67%	-94.33%	-59.77%	-116.62%	-330.09%	-	-	318.69%	-31.9%	-7.7%
Return on Invested Capital (ROIC)	-	-	-2099.52%	-1618.96%	-360.33%	-238.58%	-143.29%	3.97%	-32.95%	-11.43%
Gross Margin	77.63%	78.38%	84.28%	83%	87.24%	75.37%	45.51%	98%	100%	100%
Net Margin	-422.37%	-464.32%	-458.5%	-823.74%	-354.79%	-282.9%	-6700.93%	160.08%	-789.4%	-123.85%
Debt / Equity	-	-	-	0.75x	22.31x	-	-	0.25x	0.27x	0.26x
Interest Coverage	-	-	-	-27.84x	-8.70x	-5.44x	-2.42x	-	-	-501.05x
FCF Conversion	0.93x	0.77x	0.99x	0.81x	0.94x	0.87x	0.86x	-0.04x	4.68x	-0.34x
Revenue Growth	34.05%	-3.9%	-13.32%	-4.04%	208.38%	30.67%	-96.03%	2619.12%	-98.14%	35.25%

Revenue by Segment

	2018	2021	2022	2023	2024
License	-	1.17M	69.96M	1.3M	-
License Growth	-	-	5874.64%	-98.14%	-
Product	-	85.78M	-	-	-
Product Growth	-	-	-	-	-
Annovera	-	37.94M	-	-	-
Annovera Growth	-	-	-	-	-
Prescription Vitamins	15.04M	5.72M	-	-	-
Prescription Vitamins Growth	-	-61.94%	-	-	-
IMVEXXY R	1.06M	-	-	-	-
IMVEXXY R Growth	-	-	-	-	-

Revenue by Geography

	2018	2021	2022	2023	2024
UNITED STATES	-	-	-	-	1.12M
UNITED STATES Growth	-	-	-	-	-
Non-US	-	-	-	-	638K
Non-US Growth	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

TherapeuticsMD, Inc. (TXMD) reported $2.8M in revenue for fiscal year 2024. This represents a 34% increase from $2.1M in 2011.

TherapeuticsMD, Inc. (TXMD) grew revenue by 35.3% over the past year. This is strong growth.

Yes, TherapeuticsMD, Inc. (TXMD) is profitable, generating $0.3M in net income for fiscal year 2024 (-123.9% net margin).

Dividend & Returns

TherapeuticsMD, Inc. (TXMD) has a return on equity (ROE) of -7.7%. Negative ROE indicates the company is unprofitable.

TherapeuticsMD, Inc. (TXMD) generated $2.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

TherapeuticsMD, Inc. (TXMD) 10-Year Financial Performance & Capital Metrics

TXMD • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsWomen's Health Therapeutics

Revenue $2M +35.3%
EBITDA -$4M +47.4%
Net Income -$2M +78.8%
EPS (Diluted) -0.19 +74.3%
Gross Margin 100%
EBITDA Margin -241.4% +61.1%
Operating Margin -270.3% +58.7%
Net Margin -123.85% +84.3%
ROE -7.7% +75.9%
ROIC -11.43% +65.3%
Debt/Equity 0.26 -4.1%
Interest Coverage -501.05

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 93.0%
✓FCF machine: 41.6% free cash flow margin
✓Momentum leader: RS Rating 89 (top 11%)
✓Trading near 52-week high
✓Trading at only 0.9x book value

✗Weaknesses

✗Sales declining 48.7% over 5 years
✗Shares diluted 10.4% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-19.3%

5Y-48.72%

3Y-11.87%

TTM75.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM109.11%

EPS CAGR

10Y-

5Y-

3Y-

TTM108%

ROCE

10Y Avg-100.68%

5Y Avg-106.7%

3Y Avg-10.71%

Latest-13.58%

Peer Comparison

Women's Health Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TXMDTherapeuticsMD, Inc.	25.93M	2.24	-11.79	35.25%	10.8%	1.1%	2.82%	0.26

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	20.14M	19.36M	16.78M	16.1M	49.65M	64.87M	2.57M	69.96M	1.3M	1.76M
Revenue Growth %	0.34%	-0.04%	-0.13%	-0.04%	2.08%	0.31%	-0.96%	26.19%	-0.98%	0.35%
Cost of Goods Sold+	4.51M	4.19M	2.64M	2.74M	6.33M	15.97M	1.4M	1.4M	0	0
COGS % of Revenue	0.22%	0.22%	0.16%	0.17%	0.13%	0.25%	0.54%	0.02%	-	-
Gross Profit+	15.64M	15.17M	14.14M	13.36M	43.31M	48.9M	1.17M	68.57M	1.3M	1.76M
Gross Margin %	0.78%	0.78%	0.84%	0.83%	0.87%	0.75%	0.46%	0.98%	1%	1%
Gross Profit Growth %	0.38%	-0.03%	-0.07%	-0.06%	2.24%	0.13%	-0.98%	57.55%	-0.98%	0.35%
Operating Expenses+	100.83M	105.42M	91.77M	143.58M	194.52M	204.44M	80.75M	67.38M	9.82M	6.52M
OpEx % of Revenue	5.01%	5.45%	5.47%	8.92%	3.92%	3.15%	31.38%	0.96%	7.55%	3.7%
Selling, General & Admin	28.72M	51.35M	57.7M	115.99M	174.72M	194.01M	72.75M	56.71M	0	0
SG&A % of Revenue	1.43%	2.65%	3.44%	7.2%	3.52%	2.99%	28.27%	0.81%	-	-
Research & Development	72.04M	53.94M	33.85M	27.3M	19.79M	10.43M	0	0	0	0
R&D % of Revenue	3.58%	2.79%	2.02%	1.7%	0.4%	0.16%	-	-	-	-
Other Operating Expenses	95.72K	367.32K	695.63K	0	0	0	8M	10.66M	9.82M	6.52M
Operating Income+	-85.19M	-90.25M	-77.63M	-130.22M	-151.21M	-155.54M	-79.58M	1.19M	-8.52M	-4.76M
Operating Margin %	-4.23%	-4.66%	-4.63%	-8.09%	-3.05%	-2.4%	-30.93%	0.02%	-6.55%	-2.7%
Operating Income Growth %	-0.58%	-0.06%	0.14%	-0.68%	-0.16%	-0.03%	0.49%	1.01%	-8.16%	0.44%
EBITDA+	-85.13M	-90.12M	-77.42M	-129.93M	-149.81M	-151.47M	-78.84M	2.39M	-8.08M	-4.25M
EBITDA Margin %	-4.23%	-4.66%	-4.61%	-8.07%	-3.02%	-2.33%	-30.64%	0.03%	-6.21%	-2.41%
EBITDA Growth %	-0.58%	-0.06%	0.14%	-0.68%	-0.15%	-0.01%	0.48%	1.03%	-4.38%	0.47%
D&A (Non-Cash Add-back)	62.4K	132.45K	213.12K	293.89K	1.39M	4.07M	736K	1.2M	438.5K	509K
EBIT	-85.19M	-89.88M	-76.93M	-127.94M	-159.62M	-157.47M	-71.58M	10.66M	-8.52M	-3.49M
Net Interest Income+	17.44K	10.82K	7.7K	-4.68M	-17.38M	-28.58M	-32.92M	0	0	135.4K
Interest Income	17.44K	10.82K	7.7K	0	-	-	0	0	0	144.9K
Interest Expense	0	0	0	4.68M	17.38M	28.58M	32.92M	0	0	9.5K
Other Income/Expense	113.16K	378.14K	703.33K	-2.4M	-24.94M	-27.98M	272K	-117K	781K	2.42M
Pretax Income+	-85.08M	-89.88M	-76.93M	-132.62M	-176.15M	-183.52M	-79.31M	1.07M	-7.74M	-2.34M
Pretax Margin %	-4.22%	-4.64%	-4.58%	-8.24%	-3.55%	-2.83%	-30.82%	0.02%	-5.95%	-1.33%
Income Tax+	-17.44K	367.32K	-7.7K	0	0	0	0	0	-43K	-31K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	2.17%	104.28%	1.33%	0.93%
Net Income+	-85.08M	-89.88M	-76.93M	-132.62M	-176.15M	-183.52M	-172.41M	112M	-10.28M	-2.18M
Net Margin %	-4.22%	-4.64%	-4.58%	-8.24%	-3.55%	-2.83%	-67.01%	1.6%	-7.89%	-1.24%
Net Income Growth %	-0.57%	-0.06%	0.14%	-0.72%	-0.33%	-0.04%	0.06%	1.65%	-1.09%	0.79%
Net Income (Continuing)	-85.08M	-89.88M	-76.93M	-132.62M	-176.15M	-183.52M	-79.31M	1.07M	-7.7M	-2.31M
Discontinued Operations	0	0	0	0	0	0	-93.11M	110.92M	-2.58M	131K
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-24.56	-22.92	-18.71	-29.47	-39.79	-38.58	-25.83	-10.35	-0.74	-0.19
EPS Growth %	-0.36%	0.07%	0.18%	-0.58%	-0.35%	0.03%	0.33%	0.6%	0.93%	0.74%
EPS (Basic)	-24.56	-22.92	-18.71	-29.47	-39.79	-38.58	-25.83	-10.35	-0.55	-0.19
Diluted Shares Outstanding	3.46M	3.92M	4.11M	4.5M	4.93M	5.51M	7.96M	9.03M	10.44M	11.53M
Basic Shares Outstanding	3.46M	3.92M	4.11M	4.5M	4.93M	5.51M	7.96M	9.03M	10.44M	11.53M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	70.68M	139.41M	139.55M	186.78M	208.42M	128.4M	119.47M	55.35M	11.8M	9.93M
Cash & Short-Term Investments	64.71M	131.53M	127.14M	161.61M	160.83M	80.49M	64.91M	38.07M	4.33M	5.06M
Cash Only	64.71M	131.53M	127.14M	161.61M	160.83M	80.49M	64.91M	38.07M	4.33M	5.06M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	3.05M	4.5M	4.33M	11.06M	24.4M	32.38M	36.18M	0	3.09M	3.56M
Days Sales Outstanding	55.26	84.87	94.17	250.83	179.36	182.2	5.13K	-	866.24	738.29
Inventory	690.15K	1.08M	1.49M	3.27M	11.86M	7.99M	7.62M	0	0	0
Days Inventory Outstanding	55.9	93.86	205.6	435.67	683.37	182.63	1.98K	-	-	-
Other Current Assets	833.84K	0	0	1.9M	550.76K	4.98M	8.46M	16.12M	4.13M	1.23M
Total Non-Current Assets+	3.05M	3.06M	3.68M	25.2M	57.57M	53.21M	50M	35.11M	31.51M	28.9M
Property, Plant & Equipment	198.59K	516.84K	437.06K	472.68K	12.62M	11.51M	9.06M	7.66M	6.87M	6.1M
Fixed Asset Turnover	101.43x	37.45x	38.39x	34.06x	3.93x	5.64x	0.28x	9.14x	0.19x	0.29x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.62M	2.41M	3.1M	24.09M	44.48M	41.45M	7.14M	6.94M	6.1M	4.32M
Long-Term Investments	0	0	0	0	0	0	0	0	0	16.01M
Other Non-Current Assets	1.23M	139.04K	139.04K	639.3K	473.01K	253K	33.8M	20.51M	18.54M	2.46M
Total Assets+	73.73M	142.47M	143.23M	211.98M	265.99M	181.61M	169.47M	90.46M	43.31M	38.82M
Asset Turnover	0.27x	0.14x	0.12x	0.08x	0.19x	0.36x	0.02x	0.77x	0.03x	0.05x
Asset Growth %	0.25%	0.93%	0.01%	0.48%	0.25%	-0.32%	-0.07%	-0.47%	-0.52%	-0.1%
Total Current Liabilities+	10.67M	14.98M	13.32M	41.08M	53M	59.24M	252.89M	46.84M	6.85M	5.17M
Accounts Payable	3.13M	7.36M	4.1M	22.74M	19.18M	21.07M	3.37M	2.16M	27K	258K
Days Payables Outstanding	253.19	641.67	567.18	3.03K	1.11K	481.37	878.13	564.87	-	-
Short-Term Debt	0	0	0	0	0	0	188.27M	0	0	1.63M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	14.13M	7.06M	47.91M	30.53M	3.69M	3.16M
Current Ratio	6.63x	9.30x	10.48x	4.55x	3.93x	2.17x	0.47x	1.18x	1.72x	1.92x
Quick Ratio	6.56x	9.23x	10.36x	4.47x	3.71x	2.03x	0.44x	1.18x	1.72x	1.92x
Cash Conversion Cycle	-142.03	-462.95	-267.41	-2.35K	-242.42	-116.54	6.24K	-	-	-
Total Non-Current Liabilities+	0	0	0	73.38M	203.78M	246.37M	10.2M	8.48M	7.17M	6.29M
Long-Term Debt	0	0	0	73.38M	194.63M	237.7M	0	0	0	0
Capital Lease Obligations	0	0	0	0	9.15M	8.68M	8.06M	7.37M	6.53M	5.54M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	2.14M	1.11M	636K	744K
Total Liabilities	10.67M	14.98M	13.32M	114.46M	256.78M	305.61M	263.09M	55.31M	14.02M	11.45M
Total Debt+	0	0	0	73.38M	205.28M	248.63M	197.69M	8.76M	8.01M	7.17M
Net Debt	-64.71M	-131.53M	-127.14M	-88.23M	44.45M	168.14M	132.79M	-29.31M	3.68M	2.12M
Debt / Equity	-	-	-	0.75x	22.31x	-	-	0.25x	0.27x	0.26x
Debt / EBITDA	-	-	-	-	-	-	-	3.66x	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-12.26x	-	-
Interest Coverage	-	-	-	-27.84x	-8.70x	-5.44x	-2.42x	-	-	-501.05x
Total Equity+	63.06M	127.49M	129.91M	97.52M	9.2M	-124M	-93.62M	35.14M	29.29M	27.37M
Equity Growth %	0.3%	1.02%	0.02%	-0.25%	-0.91%	-14.48%	0.24%	1.38%	-0.17%	-0.07%
Book Value per Share	18.21	32.51	31.60	21.67	1.87	-22.49	-11.76	3.89	2.81	2.37
Total Shareholders' Equity	63.06M	127.49M	129.91M	97.52M	9.2M	-124M	-93.62M	35.14M	29.29M	27.37M
Common Stock	177.93K	196.69K	216.43K	240.46K	271.18K	300K	9K	9K	11K	11K
Retained Earnings	-219.83M	-309.7M	-386.66M	-519.28M	-695.42M	-878.95M	-1.05B	-939.36M	-949.64M	-951.82M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-152.71K	-230.62K	-372.22K	-553.63K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-79.04M	-69.14M	-76.16M	-106.81M	-165.7M	-159.47M	-147.81M	-4.08M	-48.14M	732K
Operating CF Margin %	-3.92%	-3.57%	-4.54%	-6.63%	-3.34%	-2.46%	-57.45%	-0.06%	-36.97%	0.42%
Operating CF Growth %	-0.74%	0.13%	-0.1%	-0.4%	-0.55%	0.04%	0.07%	0.97%	-10.81%	1.02%
Net Income	-85.08M	-89.88M	-76.93M	-132.62M	-176.15M	-183.52M	-79.31M	1.07M	-7.7M	-2.31M
Depreciation & Amortization	62.4K	132.45K	213.12K	293.89K	1.39M	4.07M	736K	1.19M	922K	509K
Stock-Based Compensation	7.19M	17.41M	6.89M	8.66M	10.68M	10.68M	0	11.57M	0	0
Deferred Taxes	0	0	0	216.02K	10.44M	0	0	0	0	0
Other Non-Cash Items	22.16K	2.52M	4.21K	269.86K	1.92M	12.65M	-73.83M	-13.83M	-23.92M	875K
Working Capital Changes	-1.24M	664.75K	-6.34M	16.36M	-14M	-3.34M	4.59M	-4.09M	-17.45M	1.66M
Change in Receivables	-917.66K	-3.98M	167.69K	-6.95M	-13.64M	-8.22M	-4.33M	0	0	0
Change in Inventory	491.96K	-386.17K	-409.04K	-1.78M	-8.59M	-3.34M	-711K	0	0	0
Change in Payables	-3.2M	4.23M	-3.26M	18.65M	-3.56M	1.89M	-1.06M	-1.21M	-2.13M	231K
Cash from Investing+	-584.36K	-1.26M	-827.11K	-21.5M	-23.91M	-1.6M	-2.22M	223.48M	0	0
Capital Expenditures	-584.36K	-1.24M	-827.11K	-21.32M	-23.89M	-207K	-2.22M	-355K	0	0
CapEx % of Revenue	0.03%	0.06%	0.05%	1.32%	0.48%	0%	0.86%	0.01%	36.97%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-419.1K	-14.04K	-765.29K	-175.41K	-20.42K	-1.39M	0	223.83M	0	0
Cash from Financing+	92.97M	137.23M	72.58M	162.79M	188.83M	80.72M	134.67M	-235.21M	3.15M	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.6M	2.36M	4.01M	-2.12M	-6.54M	-978K	0	-1.27M	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-79.63M	-70.38M	-76.98M	-128.13M	-189.59M	-161.07M	-147.84M	-4.43M	0	732K
FCF Margin %	-3.95%	-3.64%	-4.59%	-7.96%	-3.82%	-2.48%	-57.46%	-0.06%	-	0.42%
FCF Growth %	-0.73%	0.12%	-0.09%	-0.66%	-0.48%	0.15%	0.08%	0.97%	1%	-
FCF per Share	-22.99	-17.95	-18.73	-28.47	-38.48	-29.22	-18.57	-0.49	-	0.06
FCF Conversion (FCF/Net Income)	0.93x	0.77x	0.99x	0.81x	0.94x	0.87x	0.86x	-0.04x	4.68x	-0.34x
Interest Paid	0	0	0	0	0	25.85M	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-152.67%	-94.33%	-59.77%	-116.62%	-330.09%	-	-	318.69%	-31.9%	-7.7%
Return on Invested Capital (ROIC)	-	-	-2099.52%	-1618.96%	-360.33%	-238.58%	-143.29%	3.97%	-32.95%	-11.43%
Gross Margin	77.63%	78.38%	84.28%	83%	87.24%	75.37%	45.51%	98%	100%	100%
Net Margin	-422.37%	-464.32%	-458.5%	-823.74%	-354.79%	-282.9%	-6700.93%	160.08%	-789.4%	-123.85%
Debt / Equity	-	-	-	0.75x	22.31x	-	-	0.25x	0.27x	0.26x
Interest Coverage	-	-	-	-27.84x	-8.70x	-5.44x	-2.42x	-	-	-501.05x
FCF Conversion	0.93x	0.77x	0.99x	0.81x	0.94x	0.87x	0.86x	-0.04x	4.68x	-0.34x
Revenue Growth	34.05%	-3.9%	-13.32%	-4.04%	208.38%	30.67%	-96.03%	2619.12%	-98.14%	35.25%

Revenue by Segment

	2018	2021	2022	2023	2024
License	-	1.17M	69.96M	1.3M	-
License Growth	-	-	5874.64%	-98.14%	-
Product	-	85.78M	-	-	-
Product Growth	-	-	-	-	-
Annovera	-	37.94M	-	-	-
Annovera Growth	-	-	-	-	-
Prescription Vitamins	15.04M	5.72M	-	-	-
Prescription Vitamins Growth	-	-61.94%	-	-	-
IMVEXXY R	1.06M	-	-	-	-
IMVEXXY R Growth	-	-	-	-	-

Revenue by Geography

	2018	2021	2022	2023	2024
UNITED STATES	-	-	-	-	1.12M
UNITED STATES Growth	-	-	-	-	-
Non-US	-	-	-	-	638K
Non-US Growth	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

TherapeuticsMD, Inc. (TXMD) reported $2.8M in revenue for fiscal year 2024. This represents a 34% increase from $2.1M in 2011.

TherapeuticsMD, Inc. (TXMD) grew revenue by 35.3% over the past year. This is strong growth.

Yes, TherapeuticsMD, Inc. (TXMD) is profitable, generating $0.3M in net income for fiscal year 2024 (-123.9% net margin).

Dividend & Returns

TherapeuticsMD, Inc. (TXMD) has a return on equity (ROE) of -7.7%. Negative ROE indicates the company is unprofitable.

TherapeuticsMD, Inc. (TXMD) generated $2.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.